Abstract: Provided are an antibody or antigen binding fragment thereof that binds to CD70 for use in treating a myeloid malignancy in a human subject, who is resistant to BCL-2 inhibitor treatment and methods of treating a myeloid malignancy in a subject, said method comprising (a) selecting a human subject having a myeloid malignancy that has a reduced sensitivity or is refractory to a BCL-2 inhibitor; and (b) administering to the subject an antibody or antigen binding fragment thereof that binds to CD70. In certain embodiments, the myeloid malignancy is acute myeloid leukemia (AML). In certain embodiments, the antibody that binds to CD70 is cusatuzumab. In certain embodiments, a BCL-2 inhibitor is co-administered with the antibody or antigen binding fragment thereof that binds to CD70. In certain embodiments, the BCL-2 inhibitor is venetoclax.

Abstract: Described herein are panel coating compositions, building panel and a ceiling panel assembly having such coating compositions. The coating compositions are useful in obtaining stable and splotch-free finished paint on large panels.

Abstract: A hemostatic composition is provided. The hemostatic composition includes a hemostatically effective amount of a hemostatic agent that includes a nanoparticle and a polyphosphate polymer attached to the nanoparticle. Also provided are medical devices and methods of use to promote blood clotting.

Abstract: A system for categorizing, visualizing, and recommending Cannabis products based on objective data of the chemical composition of products is described. This system allows Cannabis products to be visualized and compared based on their chemical composition, even by laypeople with little or no knowledge of the underlying objective data. A recommendation system is built upon this which can recommend products for consumption, including a user interface for receiving user input, which includes at least one of demographic data, desired level of psychoactivity, or prior experience with the product, a merchant interface for receiving merchant input, including at least one of general data descriptive of the regulated product, lab data descriptive of the regulated products chemical composition, and user data descriptive of subjective effects of the regulated product on a user; and a decision engine making a recommendation of product according to correlation of the lab data with the user data.

Abstract: A method of coating a polymer surface, the method comprising: providing a polymer having a surface, optionally, treating at least a portion of the polymer surface with an oxidising agent, treating at least a portion of the polymer surface with a composition comprising a polysaccharide, oligosaccharide, polyol or mixture thereof, and incubating the treated polymer with the composition for a predetermined time. Also disclosed are polymers comprising such a coating, vessels comprising such coated polymers and medicals devices comprising such polymers.

Abstract: This present invention relates to a face mask with an integrated communication system that ensures the safety of the wearer while allowing the same to effectively communicate with others while wearing the face mask. The face mask features a voice modulator having a microphone and a speaker removably attached to the mask body. The wearer can easily speak into the microphone and the voice of the wearer is captured by the microphone and is clearly projected and modulated by the speaker. Additionally, the wearer may adjust the volume of the speaker as per the needs and requirements of the wearer.

Abstract: Systems and methods for inhibiting atherosclerosis using FoxP3+ CD8 T-cells (TcREG). Osteoclasts are induced to produce FoxP3+ CD8 T-cells (TcREG) through introduction of a low-dose of a RANK agonist such as RANKL. The RANKL was found to best work when provided in accordance with a schedule resulting in a pulsed administration.

Abstract: Systems and methods for inhibiting atherosclerosis using FoxP3+ CD8 T-cells (TcREG). Osteoclasts are induced to produce FoxP3+ CD8 T-cells (TcREG) through introduction of a low-dose of a RANK agonist suck as RANKL. The RANKL was found to best work when provided in accordance with a schedule resulting in a pulsed administration.

Abstract: Systems and methods for inhibiting atherosclerosis using FoxP3+ CD8 T-cells (TcREG). Osteoclasts are induced to produce FoxP3+ CD8 T-cells (TcREG) through introduction of a low-dose of a RANK agonist such as RANKL. The RANKL was found to best work when provided in accordance with a schedule resulting in a pulsed administration.

Abstract: Systems and methods for inhibiting atherosclerosis using FoxP3+ CD8 T-cells (TcREG). Osteoclasts are induced to produce FoxP3+ CD8 T-cells (TcREG) through introduction of a low-dose of a RANK agonist suck as RANKL. The RANKL was found to best work when provided in accordance with a schedule resulting in a pulsed administration.

Abstract: The invention provides methods of determining whether a cancer in a subject is responsive to anti-TGF-? therapy. In some embodiments, the invention further provides for the administration of an anti-TGF-? therapy cancer therapy to the subject.

Abstract: The invention provides a method of treating cancer in a subject comprising administering to said subject an miRNA that inhibits Six1. In some embodiments, the invention further provides for the administration of a second cancer therapy to the subject.

Abstract: The present invention is directed to methods and compositions wherein nucleic acids are associated with a solid phase that comprises a carboxylated substrate. In specific embodiments, precipitation of the nucleic acids occurs in the absence of salt.

Abstract: The present invention is directed to methods and compositions wherein nucleic acids are associated with a solid phase that comprises a carboxylated substrate. In specific embodiments, precipitation of the nucleic acids occurs in the absence of salt.

Abstract: The present invention is directed to methods and compositions wherein nucleic acids are associated with a solid phase that comprises a carboxylated substrate. In specific embodiments, precipitation of the nucleic acids occurs in the absence of salt.